Biocon Biologics set to reap Biosimilar Insulin Glargine Opportunity in US
Summary : Drugmaker is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and profit…
Summary : Drugmaker is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and profit…
Synopsis: In June, globe-trotting contract manufacturer Fujifilm Diosynth Biotechnologies unveiled an $850 million outlay to boost biologics capacity in the U.S. and…
Novartis says that the U.S. and European regulators have accepted its marketing applications for CAR-T cell therapy Kymriah (Tisagenlecleucel) as third-line therapy…